Stephen L. Hauser | Academic Influence

Stephen L. Hauser's AcademicInfluence.com Rankings

Stephen L. Hauser

Philosophy

#3867

World Rank

#6173

Historical Rank

#1188

USA Rank

Logic

#2197

World Rank

#3133

Historical Rank

#547

USA Rank

philosophy Degrees

Download Badge

Philosophy

Stephen L. Hauser's Degrees

Doctorate Medicine Harvard University

Why Is Stephen L. Hauser Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Stephen L. Hauser is a professor of the Department of Neurology at the University of California, San Francisco specializing in immune mechanisms and multiple sclerosis . He has contributed to the establishment of consortia that have identified more than 50 gene variants that contribute to MS risk.

(See a Problem?)

Stephen L. Hauser's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) (2511)
Risk alleles for multiple sclerosis identified by a genomewide study. (2007) (1380)
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (2008) (1332)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis (2013) (1170)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) (1170)
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) (1107)
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. (2011) (983)
Identification of autoantibodies associated with myelin damage in multiple sclerosis (1999) (895)
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. (1983) (833)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (2009) (799)
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial (2009) (784)
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration (2006) (760)
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex (1996) (681)
Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis (2007) (660)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial (2011) (625)
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models (2017) (593)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
Neuromyelitis optica. (2002) (485)
Methods for high-density admixture mapping of disease genes. (2004) (477)
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis (2010) (466)
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. (2009) (464)
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS? (2010) (438)
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. (1980) (438)
Genome-wide patterns of population structure and admixture in West Africans and African Americans (2009) (426)
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis (2014) (403)
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions (1986) (402)
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis (2009) (400)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. (2010) (388)
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis (2008) (340)
Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. (1995) (339)
Late Complications of Immune Deviation Therapy in a Nonhuman Primate (1996) (337)
Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. (2004) (334)
Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410 (2000) (325)
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. (2006) (310)
Long‐term evolution of multiple sclerosis disability in the treatment era (2016) (308)
A high-density screen for linkage in multiple sclerosis. (2005) (308)
Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis (1996) (307)
Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen‐specific antibody mediation (1999) (305)
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial (2017) (299)
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. (2003) (299)
Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. (1998) (290)
The genetics of multiple sclerosis: an up‐to‐date review (2012) (285)
Cytokine accumulations in CSF of multiple sclerosis patients (1990) (284)
The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. (2008) (271)
A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility (2005) (271)
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis (2004) (263)
Class II HLA interactions modulate genetic risk for multiple sclerosis (2015) (262)
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases (2009) (256)
Incidental MRI anomalies suggestive of multiple sclerosis (2009) (252)
High density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis (2014) (250)
Epinephrine-induced changes in the distribution of lymphocyte subsets in peripheral blood of humans. (1983) (248)
IL2RA Genetic Heterogeneity in Multiple Sclerosis and Type 1 Diabetes Susceptibility and Soluble Interleukin-2 Receptor Production (2009) (244)
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis (1993) (243)
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis (2012) (237)
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. (2010) (236)
Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System (2000) (230)
A susceptibility locus for multiple sclerosis is linked to the T cell receptor β chain complex (1989) (222)
Ofatumumab versus Teriflunomide in Multiple Sclerosis. (2020) (220)
Treatment of Multiple Sclerosis: A Review. (2020) (217)
Silent progression in disease activity–free relapsing multiple sclerosis (2019) (216)
B cell exchange across the blood-brain barrier in multiple sclerosis. (2012) (204)
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients (2014) (203)
The role of the CD58 locus in multiple sclerosis (2009) (200)
Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study (2006) (198)
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis (2014) (187)
Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. (2001) (185)
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. (1995) (181)
A second major histocompatibility complex susceptibility locus for multiple sclerosis (2007) (181)
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability (2011) (180)
Multiple sclerosis: Prospects and promise (2013) (179)
Cognitive function in recent-onset demyelinating diseases. (1986) (178)
Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation (2011) (165)
B‐cell Therapy for Multiple Sclerosis: Entering an era (2018) (164)
Spinal cord gray matter atrophy correlates with multiple sclerosis disability (2014) (163)
Genetic basis for clinical expression in multiple sclerosis. (2002) (159)
The expanding genetic overlap between multiple sclerosis and type I diabetes (2009) (157)
HLA Diversity in the 1000 Genomes Dataset (2014) (151)
Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. (2013) (149)
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring (2007) (146)
Multiple sclerosis: Genomic rewards (2001) (144)
Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. (2012) (143)
Side effect profile of interferon beta-lb in MS (1996) (142)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials (2020) (137)
Immunohistochemical staining of human brain with monoclonal antibodies that identify lymphocytes, monocytes, and the Ia antigen (1983) (136)
Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease (2018) (136)
Stimulation of matrix metalloproteinase‐dependent migration of T cells by eicosanoids (1995) (135)
CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis (2000) (133)
Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis (1995) (131)
Harrisons principles of internal medicine - 15th edition (2001) (130)
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis (2017) (127)
Immune Responses Against the Myelin/Oligodendrocyte Glycoprotein in Experimental Autoimmune Demyelination (2001) (125)
Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. (2002) (123)
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor (2009) (123)
The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. (2005) (121)
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. (2006) (115)
Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination (2004) (115)
Opposing T Cell Responses in Experimental Autoimmune Encephalomyelitis (2019) (112)
Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. (2010) (111)
The role of prolactin in autoimmune demyelination: Suppression of experimental allergic encephalomyelitis by bromocriptine (1991) (110)
Infliximab for the treatment of CNS sarcoidosis (2017) (110)
Multiple sclerosis susceptibility alleles in African Americans (2009) (109)
Analysis of human T-lymphotropic virus sequences in multiple sclerosis tissue (1986) (108)
Refining genetic associations in multiple sclerosis (2008) (108)
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci (2009) (107)
In healthy primates, circulating autoreactive T cells mediate autoimmune disease. (1994) (106)
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. (2019) (105)
Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event (2008) (105)
Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. (1997) (105)
Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination (2002) (102)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
Extended major histocompatibility complex haplotypes in patients with multiple sclerosis (1989) (98)
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis (2019) (97)
A meta-analysis of genomic screens in multiple sclerosis. The Transatlantic Multiple Sclerosis Genetics Cooperative. (2001) (96)
Rituximab before and during pregnancy (2018) (95)
Gut microbiota–specific IgA+ B cells traffic to the CNS in active multiple sclerosis (2020) (95)
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns (2015) (94)
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. (2009) (94)
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions (2018) (92)
Neuroimmunology I: Immunoregulation in neurological disease (1982) (90)
Multiple susceptibility loci for multiple sclerosis. (2002) (89)
APOE epsilon variation in multiple sclerosis susceptibility and disease severity (2006) (89)
A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis (2020) (87)
Immunoregulatory T‐cells and lymphocytotoxic antibodies in active multiple sclerosis: Weekly analysis over a six‐month period (1983) (86)
Enhancing linkage analysis of complex disorders: an evaluation of high-density genotyping. (2004) (86)
Creation of a model for multiple sclerosis in Callithrix jacchus marmosets (1997) (85)
Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus (2001) (84)
Aggregation of multiple sclerosis genetic risk variants in multiple and single case families (2011) (84)
Uncoupling the Roles of HLA-DRB1 and HLA-DRB5 Genes in Multiple Sclerosis1 (2008) (84)
Familial effects on the clinical course of multiple sclerosis (2006) (82)
In vivo evidence of glutamate toxicity in multiple sclerosis (2014) (82)
Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. (2015) (81)
Tumor necrosis factor (TNF) microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases associated with the major histocompatibility complex and TNF secretion. (1996) (81)
Men transmit MS more often to their children vs women (2006) (80)
Natural killer cell activity in multiple sclerosis. (1981) (78)
Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study (2019) (77)
Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. (2005) (75)
In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses (2014) (75)
Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen (1999) (74)
Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis (2003) (74)
Color vision is strongly associated with retinal thinning in multiple sclerosis (2012) (74)
Role of B Cells in Multiple Sclerosis and Related Disorders (2020) (73)
Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. (2013) (72)
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci (2010) (72)
The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β (2002) (71)
Harrison's Neurology in Clinical Medicine (2013) (71)
Pan-viral serology implicates enteroviruses in acute flaccid myelitis (2019) (70)
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. (2017) (70)
Vitamin D in African Americans with multiple sclerosis (2011) (70)
Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility (2010) (70)
PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients (2001) (69)
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies (2016) (68)
CSF cells in multiple sclerosis (1983) (67)
Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data (2011) (66)
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. (2019) (65)
Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. (2014) (65)
Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis (2004) (64)
Substance P immunoreactive astrocytes are present in multiple sclerosis plaques (1989) (63)
Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates (2001) (63)
An ImmunoChip study of multiple sclerosis risk in African Americans. (2015) (60)
The T‐cell response to myelin basic protein in familial multiple sclerosis: Diversity of fine specificity, restricting elements, and T‐cell receptor usage (1993) (60)
Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. (1984) (60)
Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures (2009) (60)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial (2020) (60)
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. (2016) (59)
Five years of ocrelizumab in relapsing multiple sclerosis (2020) (59)
A second-generation genomic screen for multiple sclerosis. (2004) (59)
Diagnostic criteria for multiple sclerosis research involving multiply affected families. (1991) (59)
Genetics of Demyelinating Diseases (1996) (58)
A membrane transporter mediates access of uridine 5'-diphosphoglucuronic acid from the cytosol into the endoplasmic reticulum of rat hepatocytes: implications for glucuronidation reactions. (1988) (57)
Osteopontin polymorphisms and disease course in multiple sclerosis (2003) (57)
A Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01 (2010) (56)
The HLA locus and multiple sclerosis in Sicily (2005) (55)
A genome-wide association study of brain lesion distribution in multiple sclerosis. (2013) (55)
Childhood multiple sclerosis: Clinical features and demonstration of changes in T cell subsets with disease activity (1982) (55)
Age, Gender and Normalization Covariates for Spinal Cord Gray Matter and Total Cross-Sectional Areas at Cervical and Thoracic Levels: A 2D Phase Sensitive Inversion Recovery Imaging Study (2015) (55)
Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis (2019) (55)
Xylosylation and glucuronosylation reactions in rat liver Golgi apparatus and endoplasmic reticulum. (1986) (54)
Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. (1986) (54)
Body mass index, but not vitamin D status, is associated with brain volume change in MS (2018) (54)
Multifactor dimensionality reduction reveals gene–gene interactions associated with multiple sclerosis susceptibility in African Americans (2006) (54)
Genetic risk variants in African Americans with multiple sclerosis (2013) (54)
Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15. (2006) (53)
Mitochondrial DNA sequence variation in multiple sclerosis (2015) (53)
Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease (1992) (52)
CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. (2010) (50)
Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS (2000) (49)
Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex. (2011) (49)
Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon (1999) (49)
Precision medicine in chronic disease management: The multiple sclerosis BioScreen (2014) (48)
Chronic Antral Ulcer Associated With Gastroduodenal Lymphocytic Phlebitis (2004) (48)
Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis (2009) (48)
Identification of MS-specific serum miRNAs in an international multicenter study (2018) (47)
Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis (2014) (47)
Insertion/deletion-related polymorphisms in the human T cell receptor beta gene complex (1989) (46)
Cyclophosphamide and plasma exchange in multiple sclerosis (1991) (46)
Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity (2013) (45)
B-Cell Therapies in Multiple Sclerosis. (2019) (45)
KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19 (2022) (45)
Altered blood T-cell subsets in patients with multiple sclerosis (1984) (45)
Multiple lessons for multiple sclerosis. (2008) (44)
Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis (2017) (44)
No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis (2013) (43)
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis (2019) (42)
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. (2005) (41)
Multiple sclerosis sibling pairs (1990) (41)
A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson’s disease (2019) (41)
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018) (41)
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis (2021) (40)
Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis (2018) (40)
Mapping gene activity in complex disorders: Integration of expression and genomic scans for multiple sclerosis (2005) (40)
Genetic aspects of multiple sclerosis. (1999) (40)
Contribution of normal aging to brain atrophy in MS (2019) (39)
CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. (2000) (39)
Refining the association of MHC with multiple sclerosis in African Americans. (2010) (38)
Variation within DNA repair pathway genes and risk of multiple sclerosis. (2010) (38)
Complex gene–gene interactions in multiple sclerosis: a multifactorial approach reveals associations with inflammatory genes (2006) (38)
4‐aminopyridine: New life for an old drug (2010) (36)
A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis (2019) (36)
Evidence of novel fine-scale structural variation at autism spectrum disorder candidate loci (2012) (36)
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial (2017) (36)
In depth comparison of an individual’s DNA and its lymphoblastoid cell line using whole genome sequencing (2012) (35)
Mayo clinic gastroenterology and hepatology board review (2004) (34)
Linkage and association analysis of chromosome 19q13 in multiple sclerosis (2001) (34)
An antispasticity effect of threonine in multiple sclerosis. (1992) (34)
Autoimmunity following viral infection: demonstration of monoclonal antibodies against normal tissue following infection of mice with reovirus and demonstration of shared antigenicity between virus and lymphocytes (1984) (34)
Experimental allergic encephalomyelitis in cynomolgus monkeys. Quantitation of T cell responses in peripheral blood. (1992) (33)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (33)
SNPs in Multi-Species Conserved Sequences (MCS) as useful markers in association studies: a practical approach (2007) (33)
A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility (2010) (33)
Subcellular distribution and regulation of hepatic bilirubin UDP-glucuronyltransferase. (1984) (33)
Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis (2018) (33)
The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis. (2007) (32)
2D phase‐sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times (2015) (32)
Abnormalities on ERCP in a case of human fascioliasis. (1984) (31)
Genetic associations with brain cortical thickness in multiple sclerosis (2015) (31)
Power estimation for non-standardized multisite studies (2016) (31)
Genetic burden in multiple sclerosis families (2013) (31)
P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions (2020) (30)
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis (2019) (29)
Sequence variation in the transforming growth factor-β1 (TGFB1) gene and multiple sclerosis susceptibility (2001) (29)
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO (2020) (29)
A smartphone sensor-based digital outcome assessment of multiple sclerosis (2021) (28)
Telomere Length Is Associated with Disability Progression in Multiple Sclerosis (2019) (28)
Genetics of multiple sclerosis. (2005) (28)
Heterogeneity at the HLA-DRB 1 locus and risk for multiple sclerosis (2006) (27)
The Use of Cyclophosphamide in the Treatment of Multiple Sclerosis a (1984) (26)
High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display (2020) (26)
Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis (2010) (26)
Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. (2000) (26)
Hollow visceral myopathy: a light- and electron-microscopic study. (1982) (26)
Formation, hepatic metabolism, and transport of bile pigments: a status report. (1988) (26)
Linkage analysis of candidate myelin genes in familial multiple sclerosis (1999) (25)
SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients (2011) (25)
A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis (2010) (24)
Multiple sclerosis and oligodendroglioma (2001) (24)
Neuroimmunology II: Antigenic specificity of the nervous system (1982) (24)
Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross‐Sectional and Gray Matter Areas (2019) (24)
Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA) (2002) (24)
Lymphocytapheresis in chronic progressive multiple sclerosis (1984) (23)
Investigation of seven proposed regions of linkage in multiple sclerosis: an American and French collaborative study (2004) (22)
Intrahepatic biliary cystadenoma (1986) (22)
Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis (2020) (22)
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis (2021) (22)
Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies (2016) (22)
Lyt-1 cells mediate acute murine experimental allergic encephalomyelitis. (1984) (21)
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course (2022) (21)
Natalizumab: Immune effects and implications for therapy (2006) (21)
Regulation of bilirubin glucuronide synthesis in primate (Macaca fascicularis) liver. Kinetic analysis of microsomal bilirubin uridine diphosphate glucuronyltransferase. (1986) (21)
Ovarian aging is associated with gray matter volume and disability in women with MS (2018) (20)
Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis (2016) (20)
Tumor necrosis factor: Immunogenetics and disease (1995) (20)
Small Bowel and Nutrition (2005) (20)
Lymphocyte capping in muscular dystrophy (1979) (20)
Approved and Future Pharmacotherapy for Multiple Sclerosis (2002) (20)
Analysis of IL4R haplotypes in predisposition to multiple sclerosis (2004) (20)
Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis. (2019) (20)
Genetic variation in the odorant receptors family 13 and the mhc loci influence mate selection in a multiple sclerosis dataset (2010) (20)
Evidence for CRHR1 in multiple sclerosis using supervised machine learning and meta-analysis in 12,566 individuals. (2010) (19)
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts (2018) (19)
The Human T Cell Response to Myelin Oligodendrocyte Glycoprotein: A Multiple Sclerosis Family-Based Study1 (2002) (19)
Antigen Presentation by B Cells in Multiple Sclerosis. (2021) (19)
Early editorial manuscript screening versus obligate peer review: A randomized trial (2007) (19)
Enhancing ties between academia and industry to improve health (2011) (19)
Harnessing electronic medical records to advance research on multiple sclerosis (2019) (19)
A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome. (2015) (18)
Onset of secondary progressive MS after long‐term rituximab therapy – a case report (2016) (17)
Examination of seven candidate regions for multiple sclerosis: strong evidence of linkage to chromosome 1q44 (2006) (17)
Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial. (1983) (17)
Lymphocyte capping in duchenne muscular dystrophy. (1979) (17)
Characterization of the expressed immunoglobulin IGHV repertoire in the New World marmoset Callithrix jacchus (2001) (17)
T Cell Subsets in Patients with Multiple Sclerosis: An Overview a (1984) (16)
Fighting decision fatigue (2012) (15)
Marketing and drug costs: Who is laughing and crying? (2007) (15)
Balancing risk and reward: The question of natalizumab (2009) (15)
The beautiful and ethereal neurological exam: An appeal for research (2011) (15)
Redistribution of Lyt-bearing T cells in acute murine experimental allergic encephalomyelitis: selective migration of Lyt-1 cells to the central nervous system is associated with a transient depletion of Lyt-1 cells in peripheral blood. (1984) (15)
Comprar Harrison's Principles of Internal Medicine, Self-Assessment and Board Review | Joseph Loscalzo | 9780071496193 | Mcgraw-Hill Education (2008) (15)
Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004) (2016) (15)
Fos RNA accumulation in multiple sclerosis white matter tissue (1991) (15)
Segregation of immunoglobulin heavy chain constant region genes in multiple sclerosis sibling pairs (1993) (14)
Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. (1999) (14)
T‐Cell Receptor Genes (1995) (14)
Interaction of uridine 5'-diphosphoglucuronic acid with microsomal UDP-glucuronosyltransferase in primate liver: the facilitating role of uridine 5'-diphospho-N-acetylglucosamine. (1988) (14)
Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. (2020) (14)
Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004) (2013) (14)
Immunoblot analysis of circulating antibodies against muscle proteins in amyotrophic lateral sclerosis and other neurologic diseases (1986) (14)
Large-scale gene-expression studies and the challenge of multiple sclerosis (2002) (14)
pRNFL as a marker of disability worsening in the medium/long term in patients with MS (2018) (14)
P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies (2017) (14)
Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients (2018) (13)
Clonally restricted B cells in peripheral blood of multiple sclerosis patients: Kappa/lambda staining patterns (1982) (13)
Vitamin D status predicts new brain MRI activity in multiple sclerosis (2012) (13)
Diagnosing multiple sclerosis: art and science (2017) (13)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
New insights into the genetics of multiple sclerosis. (2002) (12)
Treatment of Multiple Sclerosis (1994) (12)
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years (2022) (12)
Ataxin-1 regulates B cell function and the severity of autoimmune experimental encephalomyelitis (2020) (11)
Basic and clinical research: What is the most appropriate weighting in a public investment portfolio? (2006) (11)
Allelic association of sequence variants in the herpes virus entry mediator-B gene (PVRL2) with the severity of multiple sclerosis (2006) (11)
The challenge of publishing newsworthy epidemiology (2010) (11)
T-cell receptors: germline polymorphism and patterns of usage in demyelinating diseases. (1992) (11)
Inhibition of allergic encephalomyelitis in marmosets by vaccination with recombinant vaccinia virus encoding for myelin basic protein (1997) (11)
Genetic contribution to multiple sclerosis risk among Ashkenazi Jews (2015) (10)
T2 clinical research: Judgment day (2008) (10)
Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS (2020) (10)
Multiple sclerosis drugs: Sticker shock (2012) (10)
Two genetic variants explain the association of European ancestry with multiple sclerosis risk in African-Americans (2020) (10)
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry (2021) (10)
What to tell patients with their first attack of multiple sclerosis. (1996) (10)
Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study (2020) (10)
Crowdsourcing scientific innovation (2009) (10)
Linear IgA bullous dermatosis: an association with ulcerative colitis versus renal cell carcinoma. (2003) (10)
Unusual organization of the human T-cell receptor beta-chain gene complex is linked to recombination hotspots. (1993) (10)
Retinal INL Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration? (2020) (10)
A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development (2020) (10)
Clinical trials: rising costs limit innovation (2007) (10)
Long-term Reduction of Relapse Rate and Confirmed Disability progression after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (2018) (9)
Scripts for science: A new wrinkle on academic ties with industry (2008) (9)
T‐cell subsets in human autoimmune diseases (1982) (9)
Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. (2022) (9)
Comparative effectiveness research in the neurosciences (2009) (9)
Multiple Sclerosis: B Cells Take Center Stage (2018) (9)
Biased expression of T cell receptor genes characterizes activated T cells in multiple sclerosis cerebrospinal fluid (1996) (9)
Follow-up examination of linkage and association to chromosome 1q43 in multiple sclerosis (2009) (9)
What ethics integration looks like in neuroscience research (2014) (8)
Immunosuppression for multiple sclerosis. (1983) (8)
Personalized genetic scans: With gifts like these… (2009) (8)
Restrictive and diversifying elements of the anti-myelin/oligodendrocyte glycoprotein antibody response in primate experimental allergic encephalomyelitis (2006) (8)
Exploration of Anti-Yo and Anti-Hu paraneoplastic neurological disorders by PhIP-Seq reveals a highly restricted pattern of antibody epitopes (2018) (8)
Fred Plum (1924–2010) and the founding of the Annals of Neurology (2010) (8)
Sex-specific Tau methylation patterns and synaptic transcriptional alterations are associated with neural vulnerability during chronic neuroinflammation. (2019) (8)
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II (2022) (8)
Decoding Multiple Sclerosis (2011) (8)
Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled Studies (S49.003) (2016) (8)
Neurologic education 2011: New challenges and opportunities (2010) (7)
A status report on neuroscience research, without grade inflation (2006) (7)
Increased IgG secretion by unstimulated mononuclear cells in active multiple sclerosis and functional assessment of the T8 subset. (1985) (7)
Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (2018) (7)
Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Progressive Disease (P1.420) (2018) (7)
Time to Cognitive Worsening in Patients With Relapsing Multiple Sclerosis in Ocrelizumab Phase III Trials (S44.005) (2018) (7)
Interferons in relapsing remitting multiple sclerosis (2003) (7)
Progress in Multiple Sclerosis Research: An Example of Bedside to Bench. (2020) (7)
Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis (2001) (7)
Specific hypomethylation programs underpin B cell activation in early multiple sclerosis (2021) (7)
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial (2018) (6)
Advances in Imaging Multiple Sclerosis (2017) (6)
Neurology and medical devices (2006) (6)
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed. (2015) (6)
Electronic Health Record Technology Designed for the Clinical Encounter: MS NeuroShare. (2020) (6)
Genetic variation in nitric oxide synthase 2A (NOS2A) and risk for multiple sclerosis (2008) (6)
Modern care for neurological problems must address waste (2012) (6)
Comprar Harrison's Manual of Medicine | Dennis Kasper | 9780071477437 | Mcgraw-Hill Education (2009) (6)
Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II) (S16.005) (2017) (6)
FLOODLIGHT: Remote Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Sensor-Based Outcomes Consistent With and Augmenting Conventional In-Clinic Measures (P4.382) (2018) (6)
Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis. (1982) (6)
Translational research for a new administration: What sort of change to believe in? (2008) (6)
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials (2021) (6)
Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumab in Patients With Multiple Sclerosis (N4.001) (2019) (6)
The dangers of clinical conviction: An “M&M” of endovascular therapies for stroke (2013) (6)
Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201) (2015) (5)
Prevention strategies for multiple sclerosis (1994) (5)
Getting youth in the game: Can we accelerate training for clinician‐scientists? (2010) (5)
Imaging correlates of visual function in multiple sclerosis (2020) (5)
Can industry rescue the National Institutes of Health? (2006) (5)
Fine specificities of T cell and B cell responses to myelin/oligodendrocyte glycoprotein in common marmosets (1998) (5)
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis (2020) (5)
Electronic medical records: Does it take a village or a thousand points of light? (2008) (5)
Comprar Harrison's Manual Of Medicine 19th Ed. | D. Kasper | 9780071828529 | MCGRAW HILL (2016) (5)
Matriculating the next generation of clinician‐scientists (2007) (5)
Regulation of bilirubin glucuronide synthesis in primate (Macaca fascicularis) liver (1986) (5)
Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006) (2012) (5)
Electronic medical records and the academic neurologist: When carrots turn into sticks (2012) (5)
Multiple sclerosis: two decades of progress (2022) (4)
An update on multiple sclerosis (2005) (4)
Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366) (2018) (4)
Pathogenesis of Multiple Sclerosis: Relationship to Therapeutic Strategies (1996) (4)
IOM task impossible: Set the agenda for neurological comparative effectiveness research (2009) (4)
Florbetapir: Knowing one's future (2012) (4)
Curing Multiple Sclerosis: How to Know When We're There (2021) (4)
Chapter 85 – Multiple Sclerosis (2015) (4)
Expression and Cellular Localization of Major Histocompatibility Complex Antigens in Active Multiple Sclerosis Lesions a (1988) (4)
Preliminary results of the opera i and opera ii open-label extension study (2017) (4)
Neurogenetics in the Annals: Dealing with complexity (2008) (4)
Ocrelizumab May Reduce Tissue Damage in Chronic Active Lesions as Measured by Change in T1 Hypo-Intensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis (P3.376) (2018) (4)
Reply to Dr Sethi (2013) (4)
Epidemiology in the Annals: part of the problem or the solution? (2007) (4)
Transformative research (2008) (4)
The neurologic revolving door: Time to pay attention to readmissions (2013) (4)
Serum antibodies to phosphatidylcholine in MS (2020) (4)
Beaten into action: A perspective on blood sports (2012) (4)
Biological concepts of multiple sclerosis pathogenesis and relationship to treatment (2007) (4)
The shape of things to come (2004) (4)
Extraordinary claims require extraordinary evidence (2011) (3)
That vexing problem of compensation (2008) (3)
Of ghosts and sirens: The subtlest lures of industry (2007) (3)
Economic Over‐Stimulation? (2009) (3)
Serological and metagenomic interrogation of cerebrospinal fluid implicates enteroviruses in pediatric acute flaccid myelitis (2019) (3)
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials (2022) (3)
CASE REPORT: Linear IgA Bullous Dermatosis: An Association with Ulcerative Colitis Versus Renal Cell Carcinoma (2003) (3)
061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE) (2018) (3)
More on Cetuximab in Head and Neck Cancer (2007) (3)
Recombinant therapeutics: From bench to bedside (if your health plan concurs) (2006) (3)
Gastrointestinal Manifestations of Human Immunodeficiency Virus Infection (2005) (3)
The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study (S33.006) (2017) (3)
DSM‐V: Psychodrama on the public stage (2013) (3)
Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002) (2016) (3)
Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis (2019) (3)
Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients (2022) (3)
The human T-cell receptor β-chain repertoire: longitudinal fluctuations and assessment in MHC matched populations (1993) (3)
Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.008) (2016) (3)
MR Spectroscopy Markers of Disease Progression in Multiple Sclerosis: A Clinical Validation Study (PL01.002) (2012) (3)
Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002) (2018) (3)
Sleepiness in the elderly (2006) (3)
Mechanisms of formation, hepatic transport, and metabolism of bile pigments. (1984) (3)
F.27. Meta-analysis of Genome Scans and Replication Identify CD6, ICSBP1, and TNFRSF1A as Novel Multiple Sclerosis Susceptibility Loci (2009) (3)
Atrophy of spinal cord gray matter is detectable at an early stage of multiple sclerosis (S2.003) (2017) (3)
Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis (2022) (3)
Future role of neurologists. (1994) (3)
Status report: The Annals in 2010 (2010) (3)
Accelerated Cord Atrophy Precedes Conversion to Secondary Progressive Disease in Relapsing Multiple Sclerosis (2019) (2)
145 Long-term safety of ofatumumab in patients with relapsing multiple sclerosis (2022) (2)
Global clinical trials: Challenges ahead (2011) (2)
Nerve growth factor prevents inflammation and demyelination in a non human model of multiple sclerosis (1998) (2)
Multiple sclerosis: basic immunology. (1998) (2)
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials (2018) (2)
Neurological disease on the global agenda (2008) (2)
Mechanistic and molecular aspects of hepatic bilirubin glucuronidation. (1990) (2)
Low‐grade central nervous system lymphoma: Clarity through a Hazy lens (2006) (2)
Case studies in neurology for the house officer. By Stephen L. Hauser, Lawrence P. Levitt, and Howard L. Weiner, Baltimore, Williams & Wilkins, 1986 256 pp, illustrated, $10.95 (1987) (2)
The neurological exam: Striking a nerve (2012) (2)
Gastrointestinal Manifestations of Systemic Disease (2005) (2)
Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply (2012) (2)
Searching for novelty: Challenges with open access data (2012) (2)
Robert A. Fishman, MD (1924–2012) (2013) (2)
PO129 Neda analysis by epoch in the opera studies of ocrelizumab (2017) (2)
Big neuroscience (2013) (2)
Manuscripts, Referees, and Editors (2010) (2)
Insertion/deletion-related Polymorphisms in the Human T Cell Receptor /3 Gene Complex Materials and Methods (1989) (2)
Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study (2019) (2)
Advancing ethical neuroscience (2015) (2)
Research trainees in the clinical neurosciences: Still a shallow pool (2009) (2)
Multiple sclerosis: Tip of the iceberg? (2006) (2)
Mayo Clinic Gastroenterology and Hepatology Board Review, Third Edition (2008) (2)
Haplotypic origin of beta-chain genes expressed by human T-cell clones. (1992) (2)
Note to aspiring clinician scientists: Skies are clearing (2012) (2)
P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies (2017) (2)
Peer review at National Institutes of Health: Small steps forward (2008) (2)
Neuroreconciliation and the health care debate (2010) (2)
A status report on the Annals (2008) (2)
The Value of a Case Report (2007) (2)
145 – Vascular Diseases of the Gastrointestinal Tract (2012) (2)
Molecular genotyping of the T-cell receptor beta chain in families of multiple sclerosis patients (1987) (2)
High Resolution Haplotype Analyses of Classical HLA Genes in Families With Multiple Sclerosis Highlights the Role of HLA-DP Alleles in Disease Susceptibility (2021) (2)
Scientific literacy and the media (2011) (1)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1990. A 32-year-old woman with asthma, eosinophilia, and a sensorimotor neuropathy. (1990) (1)
The MS-Associated Gut Microbiome (2017) (1)
The NIH shuffle, NCATS, and neurology (2011) (1)
Passive transfer EAE and T-cell repertoire in primates (1991) (1)
Remote Observational Research for Multiple Sclerosis (2022) (1)
Haplotypic origin of β-chain genes expressed by human T-cell clones (2004) (1)
Vitamin D Levels Are Associated with Disability and Brain Volume in Multiple Sclerosis (S50.003) (2012) (1)
Phase sensitive inversion recovery imaging of the spinal cord in clinical scan times (2013) (1)
Reviewing how we review (2013) (1)
Message from the Editor: On humility (2009) (1)
Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing-Remitting Multiple Sclerosis (S12.008) (2017) (1)
Effect of Ocrelizumab on Visual Outcomes in Patients with Baseline Visual Impairment in the OPERA Studies in Relapsing Multiple Sclerosis (2018) (1)
Erratum: Unraveling Multiple MHC Gene Associations with Systemic Lupus Erythematosus: Model Choice Indicates a Role for HLA Alleles and Non-HLA Genes in Europeans (The American Journal of Human Genetics (2012) 91 (778-793)) (2015) (1)
Waking Up to Narcolepsy (2011) (1)
Ocrelizumab Safety in Patients with Multiple Sclerosis: Updated Analyses with a Focus on Infusion-Related Reactions (2018) (1)
Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis (2019) (1)
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis (2023) (1)
KO8s are not going to the K‐9s (2007) (1)
Healthcare costs: Eden's apple? (2012) (1)
Immunoregulatory abnormalities induced by experimental reovirus infection: functional alterations in T-cell subpopulations. (1987) (1)
Review article Multiple sclerosis: Genomic rewards (2001) (1)
Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290) (2020) (1)
An election season prescription for healthcare (2008) (1)
Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions (2019) (1)
Immunoregulation in multiple sclerosis. (1983) (1)
Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. (2022) (1)
P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial (2019) (1)
In depth comparison of an individual’s DNA and its lymphoblastoid cell line using whole genome sequencing (2012) (1)
No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies (P4.391) (2017) (1)
FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis (2019) (1)
Harrison's Online Updates (2001) (1)
Blockbusters for cheap? The difficulties surrounding generic biologics (2013) (1)
In Memoriam: Robert A. Fishman, MD (1924-2012) (2013) (1)
The inheritance of T cell receptor genes in multiplex families with multiple sclerosis (1988) (1)
Are relative value units hurting healthcare? (2013) (1)
Reply to “Silent Progression or Bout Onset Progressive Multiple Sclerosis?” (2019) (1)
Mapping the human genome with newfound precision (2010) (1)
Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. (2017) (1)
B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356) (2020) (1)
NEUROLOGIC DISEASE: Risk of ALS associated with military service (2005) (1)
Multiple sclerosis: Monotherapy rules (2013) (1)
Human KIR+CD8+ T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19 (2021) (1)
Reply to “Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS” (2022) (1)
Hepatology: A textbook of liver disease (1991) (1)
60-year-old man with chronic diarrhea and peptic ulcer disease. (2015) (1)
Alkaline phosphatase activity in lymph and serum of bile duct-ligated rats. (1978) (1)
Abstracts of the 4th Meeting of the ‘Association Française pour l’Etude du Foie’ (1978) (1)
Chronic diarrhea in an HIV+ patient—something to consider in the differential (2003) (1)
Preface Harrison's Manual of Medicine (2019) (0)
Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096) (2019) (0)
The Upcoming Meeting of the ANA (2007) (0)
ACTRIMS 2019 – Invited Program (2019) (0)
No evidence of linkage of multiple sclerosis to chromosome 17q22-24 in American and French multiplex families (1999) (0)
OR.22. Dissection of the Admixture Multiple Sclerosis Susceptibility Locus On Chromosome 1 in An African-American Population (2006) (0)
Proteosome inhibitors revisited (2006) (0)
Medical prizes: Lifetime achievement awards or engines for progress? (2007) (0)
Sclerosis Patients CD20-Expressing T Cells in Multiple Rituximab Efficiently Depletes Increased (2014) (0)
P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis (2019) (0)
Disparities in care: Guilty until proven innocent (2009) (0)
Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (S46.003) (2023) (0)
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis (2017) (0)
A Predictive Autoantibody Signature in Multiple Sclerosis (2023) (0)
Thanks to Our Authors, Reviewers and Publisher (2011) (0)
Building a precision medicine delivery platform for the clinic: the UCSF BRIDGE experience. (Preprint) (2021) (0)
Journeys in Complex Genetics: Music and Mental Illness (2009) (0)
OR.102. The CD58 Pathway is Implicated in MS Susceptibility (2008) (0)
Opposing T cell responses in experimental autoimmune encephalomyelitis (2019) (0)
Pan-viral serology implicates enteroviruses in acute flaccid myelitis (2019) (0)
Multiple sclerosis (2020) (0)
PO128 Infusion-related reactions with ocrelizumab in rms and ppms (2017) (0)
Magnetic Resonance SpectroscopyMarkers of Disease Progression inMultiple Sclerosis (2014) (0)
177 Updated safety analysis of ocrelizumab in multiple sclerosis (2019) (0)
Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis (2022) (0)
Oligodendrocyte Glycoprotein: A Multiple The Human T Cell Response to Myelin (2002) (0)
Erratum: Still No Answers for Chronic Fatigue Syndrome (2011) (0)
Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013) (2023) (0)
Harrison's Online Updates (2001) (0)
Introduction to a special edition of Annals: Therapeutic prospects (2013) (0)
A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development (Preprint) (2019) (0)
Pharmacogenomic analysis of immunotherapy in multiple sclerosis (2002) (0)
Human immunogenetics: Basic principles and clinical relevance. Immunology series. Volume 43 Edited by Stephen D. Litwin. New York: Marcel dekker, inc. (1989). 856 pp. $150.00 (1989) (0)
Investigation of novel type 1 diabetes loci in multiple sclerosis (2009) (0)
Ofatumumab Impresses in Head-to-Head Phase 3 Trials in Patients With Relapsing Forms of Multiple Sclerosis (2019) (0)
PAIN MANAGEMENT: Combined opiates and gabapentin for neuropathic pain (2005) (0)
Longitudinally persistent cerebrospinal fluid B-cells resist treatment in multiple sclerosis (2018) (0)
Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes (2023) (0)
020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years (2022) (0)
Natalizumab in relapsing multiple sclerosis: appropriate patient selection, management guidelines, and a diagnostic algorithm for the differential diagnosis of new neurologic signs or symptoms (2006) (0)
Quo vadis? – peering into the future (2013) (0)
Building a Precision Medicine Delivery Platform for Clinics: The University of California, San Francisco, BRIDGE Experience (2022) (0)
High density mapping of the MHC reveals a common role for HLA- DRB1*01:03 in IBD and heterozygous advantage in ulcerative colitis (2014) (0)
Onset of clinical andMRI e ffi cacy of ocrelizumab in relapsing multiple sclerosis (0)
Concise review: the polypill in cardiovascular disease prevention (2007) (0)
Additional file 4: of Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients (2018) (0)
Books received (1989) (0)
Cutting Edge Developments in MS Research (2017) (0)
Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis (2022) (0)
Deciphering the signature injury (2012) (0)
Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change (S16.009) (2023) (0)
Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients (2018) (0)
Contribution Variation Within DNA Repair Pathway Genes and Risk of Multiple Sclerosis (2010) (0)
Apping at the Annals (2012) (0)
Grey and white matter atrophy in a large cohort of multiple sclerosis patients : Relation to MRI parameters and impact on clinical disability (2011) (0)
Cellular Immunological Studies with Monoclonal Antibodies in Neurological Diseases (1982) (0)
Miscellaneous Disorders - Questions and Answers (2011) (0)
Double vision. Hepatic foregut duplication cyst and concurrent acute gangrenous cholecystitis. (2013) (0)
Systemic lupus erythematosus (SLE) and neonatal morbidity and mortality. (1998) (0)
299 A High Density Association Study of the Extended Major Histocompatibility Locus in Ulcerative Colitis and Crohn's Disease (2008) (0)
Benefits of medical research: Hollywood weighs in (2011) (0)
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis (2019) (0)
Microsomal bilirubin udp glucuronyltransferase catalyzed formation of bilirubin diglucuronide in primate liver yet another unexpected twist (1986) (0)
Peptic Ulcer Disease (2011) (0)
Infliximab for the Treatment of CNS Sarcoidosis: Clinical and Radiological Outcomes (S9.005) (2015) (0)
Malignant middle cerebral artery stroke: Where ischemia meets the scalpel (2010) (0)
Ileal lipoma causing both gastrointestinal bleeding and intussusception (2003) (0)
Pancreas and Biliary Tree (2005) (0)
Nutritional Disorders: Vitamins and Minerals (2008) (0)
Reply (2011) (0)
Vitamin and Trace Mineral Deficiency and Excess (Chapter 326) (2018) (0)
List of contributors (2020) (0)
Colon - Questions and Answers (2011) (0)
Multiple Sclerosis Therapeutics: The genetics of multiple sclerosis (2011) (0)
Liver - Questions and Answers (2011) (0)
The role of the CD[subscript 5]8 locus in multiple sclerosis (2009) (0)
Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis (2019) (0)
BRIDGE: Bringing Precision Medicine to Clinic (2021) (0)
Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis (P8-3.004) (2023) (0)
Vascular Disorders of the Gastrointestinal Tract (2005) (0)
A High Density Association Study of the Extended Major Histocompatibility Locus in Ulcerative Colitis (2007) (0)
Consequences of a “Dropped Pass”: Liver Abscess Due to Eikenella corrodens: 580 (2007) (0)
Comprar Mayo Clinic Gastroenterology and Hepatology Board Review | Stephen Hauser | 9780199827619 | Oxford University Press (2011) (0)
Stomach - Questions and Answers (2011) (0)
Esophagus - Questions and Answers (2011) (0)
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci | NOVA. The University of Newcastle's Digital Repository (2011) (0)
Vitamins and Minerals (2005) (0)
Robert A. Fishman, MD (2013) (0)
Small Bowel and Nutrition - Questions and Answers (2011) (0)
Expression of the chemokine receptor CXCR3 and its ligand, IP-10, in macaques with experimental allergic encephalitis (1998) (0)
Contributors (2012) (0)
Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions (2019) (0)
An Enigmatic Case of Chronic Diarrhea, Deciphered: 877 (2012) (0)
Characterizing breakthroughs in hepatitis C patients who were nonresponders to interferon therapy (1998) (0)
Re: GAMES issue. (2004) (0)
Message from the editor (2006) (0)
Whole-Exome Sequencing in Multiplex Families Identifies Novel Rare Variants in Multiple Sclerosis (P05.137) (2013) (0)
Predicting Disability In The Modern MS Cohort (P4.184) (2014) (0)
Hepatology: A textbook of liver disease: By David Zakim and Thomas D. Boyer. 1706 pp. $225.00. W. B. Saunders Company, Philadelphia, Pennsylvania, 1990. ISBN: 0-72162108-2 (1991) (0)
Baseline Features of Patients With RMS in Ocrelizumab Trials OPERA I and OPERA II (2015) (0)
Favourable additional safety data for ofatumumab (2022) (0)
Liver diseases: Targeted diagnosis and therapy using specific receptors and ligands. Edited by G.Y. Wu and C.H. Wu, 356 pp. New York: Marcel Dekker, Inc., 1991. $110 (1991) (0)
Hemochromatosis and the heart. (1993) (0)
Neurology: Violence at home (2013) (0)
Hepatic Manifestations of Systemic Diseases (2010) (0)
Progress report on the Annals (2009) (0)
Pancreas and Biliary Tree - Questions and Answers (2011) (0)
Clustering of autoimmune disease in families at high risk for multiple sclerosis? – Authors' reply (2007) (0)
Accelerated Worsening in Serum Neurofilament Light Chain Levels and Multiple Sclerosis Functional Composite in Women with MS after Menopause (S9.009) (2023) (0)
034 Updated safety analysis of ocrelizumab in multiple sclerosis (2022) (0)
F.33. The IMAGEN Consortium: A High-density SNP Map of the MHC in Lupus Identifies Multiple Independent Disease-associated Variants (2009) (0)
Building a precision medicine platform for the clinic: the UCSF BRIDGE experience. (Preprint) (2021) (0)
Association of Daily Physical Activity with Cervical Spinal Cord Areas in Multiple Sclerosis (S27.009) (2023) (0)
Author Correction: Pan-viral serology implicates enteroviruses in acute flaccid myelitis (2021) (0)
EDSS and MSFC Incompletely Capture Patient Reported Disability in a Longitudinal Cohort of Patients with Multiple Sclerosis (P5.014) (2014) (0)
Living in the time of sequestration (2013) (0)
Have the Annals editors added value? (2013) (0)
Investigator balkanization (2008) (0)
144 Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis (2022) (0)
Comprar Harrison’s Neurology in Clinical Medicine | Eugene Braunwald | 9780071741033 | Mcgraw-Hill Education (2010) (0)
Genes in Multiple Sclerosis HLA-DRB 5 and HLA-DRB 1 Uncoupling the Roles of Barcellos and (2008) (0)
Late Breaking News (2007) (0)
Infliximab for the treatment of neurosarcoidosis: a multi-institutional case series (P1.335) (2017) (0)
Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis (1845) (2020) (0)

This paper list is powered by the following services:

Other Resources About Stephen L. Hauser

en.wikipedia.org

What Schools Are Affiliated With Stephen L. Hauser?

Stephen L. Hauser is affiliated with the following schools:

Image Attributions

Image Source for Stephen L. Hauser